Statin administration is associated with higher IGF-1 levels in patients without diabetes mellitus

Problems of Endocrinology Pub Date : 2018-10-06 DOI:10.14341/PROBL8759

O. Shpagina, I. Bondarenko, G. Kolesnikova

{"title":"Statin administration is associated with higher IGF-1 levels in patients without diabetes mellitus","authors":"O. Shpagina, I. Bondarenko, G. Kolesnikova","doi":"10.14341/PROBL8759","DOIUrl":null,"url":null,"abstract":"Background: Research makes it clear that the IGF-1 level correlates with cardiovascular disease, chronic heart failure, and mortality. Yet, little is known about the effect of statins on IGF-1. \nAims: to evaluate the effect of statin treatment on IGF-1 and its association with a cardiovascular risk. \nMaterial and methods: The study included 115 patients (mean age, 55.8±6.1 years) who either were overweight or had mild obesity (body mass index 28.6±3.8 kg/m2) without diabetes. Group 1 consisted of 70 patients with verified coronary artery disease receiving statin therapy; group 2 included 45 healthy subjects. Coronary angiography and treadmill test were used to diagnose coronary artery disease. Impaired glucose tolerance and total cholesterol, triglycerides, LPHD, LPLD, fibrinogen, and IGF-1 levels were evaluated in all the subjects. Heart chamber geometry was assessed by echocardiography. \nResults: The IGF-1 level was significantly higher in group 1 compared to the control group (196 and 167 ng/ml, respectively; р=0.014). Serum levels of IGF-1 were associated with duration of statin therapy (R=0.311; p=0.000), stage of hypertension (R=0.187; p=0.04), fibrinogen (R=0.274; p=0.033), TG (R=0.316; p=0.006), total cholesterol (R=–0.213; p=0.016), LPLD (R=–0.184; p=0.038), smoking (R=0.3; p=0.009), ejection fraction (R=0.298; p=0.041), end-diastolic volume (R=0.422; p=0.036), end-systolic volume (R=0.407; p=0.042), end-diastolic dimension (R=0.27; p=0.014), interventricular septal thickness (R=0.247; p=0.02), and left ventricular posterior wall thickness (R=0.258; p=0.019). Rosuvastatin dose positively correlated with the IGF-1 level (R=0.521; p=0.028). \nConclusions: Statin administration is associated with higher IGF-1 levels in patients without diabetes. High IGF-1 level correlates with the risk factors of coronary artery disease: hypertension, lipid profile, and fibrinogen level and has an adverse effect on chronic heart failure by altering the cardiac remodeling.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problems of Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/PROBL8759","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Research makes it clear that the IGF-1 level correlates with cardiovascular disease, chronic heart failure, and mortality. Yet, little is known about the effect of statins on IGF-1. Aims: to evaluate the effect of statin treatment on IGF-1 and its association with a cardiovascular risk. Material and methods: The study included 115 patients (mean age, 55.8±6.1 years) who either were overweight or had mild obesity (body mass index 28.6±3.8 kg/m2) without diabetes. Group 1 consisted of 70 patients with verified coronary artery disease receiving statin therapy; group 2 included 45 healthy subjects. Coronary angiography and treadmill test were used to diagnose coronary artery disease. Impaired glucose tolerance and total cholesterol, triglycerides, LPHD, LPLD, fibrinogen, and IGF-1 levels were evaluated in all the subjects. Heart chamber geometry was assessed by echocardiography. Results: The IGF-1 level was significantly higher in group 1 compared to the control group (196 and 167 ng/ml, respectively; р=0.014). Serum levels of IGF-1 were associated with duration of statin therapy (R=0.311; p=0.000), stage of hypertension (R=0.187; p=0.04), fibrinogen (R=0.274; p=0.033), TG (R=0.316; p=0.006), total cholesterol (R=–0.213; p=0.016), LPLD (R=–0.184; p=0.038), smoking (R=0.3; p=0.009), ejection fraction (R=0.298; p=0.041), end-diastolic volume (R=0.422; p=0.036), end-systolic volume (R=0.407; p=0.042), end-diastolic dimension (R=0.27; p=0.014), interventricular septal thickness (R=0.247; p=0.02), and left ventricular posterior wall thickness (R=0.258; p=0.019). Rosuvastatin dose positively correlated with the IGF-1 level (R=0.521; p=0.028). Conclusions: Statin administration is associated with higher IGF-1 levels in patients without diabetes. High IGF-1 level correlates with the risk factors of coronary artery disease: hypertension, lipid profile, and fibrinogen level and has an adverse effect on chronic heart failure by altering the cardiac remodeling.

查看原文本刊更多论文

他汀类药物与非糖尿病患者较高的IGF-1水平相关

研究表明，IGF-1水平与心血管疾病、慢性心力衰竭和死亡率相关。然而，我们对他汀类药物对IGF-1的影响知之甚少。目的:评价他汀类药物治疗对IGF-1的影响及其与心血管风险的关系。材料与方法:研究纳入115例无糖尿病的超重或轻度肥胖(体重指数28.6±3.8 kg/m2)患者，平均年龄55.8±6.1岁。第一组70例确诊冠心病患者接受他汀类药物治疗;第二组45名健康受试者。冠状动脉造影和跑步机试验诊断冠心病。对所有受试者的糖耐量、总胆固醇、甘油三酯、LPHD、LPLD、纤维蛋白原和IGF-1水平进行评估。超声心动图评估心室几何形状。结果:1组IGF-1水平显著高于对照组(分别为196、167 ng/ml);р= 0.014)。血清IGF-1水平与他汀类药物治疗时间相关(R=0.311;p=0.000)、高血压分期(R=0.187;p=0.04)，纤维蛋白原(R=0.274;p=0.033)， TG (R=0.316;p=0.006)、总胆固醇(R= -0.213;p=0.016)， LPLD (R= -0.184;p=0.038)，吸烟(R=0.3;p=0.009)，射血分数(R=0.298;p=0.041)，舒张末期容积(R=0.422;p=0.036)，收缩期末期容积(R=0.407;p=0.042)，舒张末期尺寸(R=0.27;p=0.014)，室间隔厚度(R=0.247;p=0.02)，左室后壁厚度(R=0.258;p = 0.019)。瑞舒伐他汀剂量与IGF-1水平呈正相关(R=0.521;p = 0.028)。结论:他汀类药物与非糖尿病患者较高的IGF-1水平相关。高IGF-1水平与冠状动脉疾病的危险因素:高血压、血脂和纤维蛋白原水平相关，并通过改变心脏重塑对慢性心力衰竭有不利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Problems of Endocrinology

自引率

0.00%

发文量